Skip to content

Trial Summary

An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Agents versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus FOLFOX or FOLFIRI In Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer

Acronym:

C4221015

ACTRN/NCT /ethics:

Scientific title:

An Open-label, Multicenter, Randomized Phase 3 Study of First-line Encorafenib Plus Cetuximab With or Without Chemotherapy Agents versus Standard of Care Therapy with a Safety Lead-in of Encorafenib and Cetuximab Plus FOLFOX or FOLFIRI In Participants with Metastatic BRAF V600E-Mutant Colorectal Cancer

Sponsor / Cooperative group:

Trial & Patient Characteristics

Cancer TypeBowel & Colon
Trial TypeTreatment
Phase-
Age Range-
Sex-
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Emailpamela.cooper@sa.gov.au
Phone08 8222 6140
Principal InvestigatorProfessor Tim Price
Recruitment StatusNot Yet Recruiting